Key Takeaways:

  • Novo Nordisk launches Ozempic pills in the US on May 4, 2026, with self-pay pricing starting at $149/month for the 1.5mg dose
  • This is the first oral medication to carry the Ozempic brand name, replacing the lesser-known Rybelsus branding
  • The pills will be available at over 70,000 pharmacies nationwide, with insurance coverage as low as $25 for eligible patients

Major Diabetes Medication Gets Pill Form Under Trusted Brand

Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes in the US. This launch represents a significant shift in how people access one of the most recognizable names in diabetes treatment, bringing the power of the Ozempic brand to a pill format for the first time.

The new Ozempic pills are essentially a rebranded and reformulated version of Rybelsus, which has been available since 2019 but struggled with market recognition. "Because Ozempic® is so well known, people often ask whether there's an oral option for people with type 2 diabetes, without realizing Rybelsus® has been available since 2019," said Ed Cinca, Senior Vice President of Marketing & Patient Solutions at Novo Nordisk Inc. "The Rybelsus brand won't be carried forward but the tablets will continue under the iconic brand of Ozempic," Cinca confirmed.

Aggressive Pricing Strategy Makes Oral Option More Accessible

Novo Nordisk has implemented a transparent pricing structure that makes the oral option competitive with other GLP-1 medications. Self-pay customers using NovoCare® Pharmacy or select telehealth providers will pay $149 for the starting dose of 1.5 mg Ozempic® pills, $199 per month for the 4 mg Ozempic® pills, and $299 per month for the 9 mg Ozempic® pills.

For those with insurance coverage, the pricing becomes even more attractive. Ozempic® pill will be covered by insurance for most people with type 2 diabetes for as little as $25 for up to a 3-month prescription. This represents a significant cost advantage over many injectable options and addresses one of the biggest barriers to GLP-1 access: affordability.

The company has also partnered with GoodRx to expand access. The agreement covers three distinct dosages with tiered monthly cash pricing: 1.5mg ($149), 4mg ($199), and 9mg ($299). With nearly 25 million monthly consumers and over one million healthcare professionals on its platform, GoodRx is uniquely positioned to bridge the gap between pharmaceutical innovation and accessibility.

Strategic Brand Consolidation in Competitive Market

The decision to retire the Rybelsus name in the US reflects the cultural phenomenon that Ozempic has become. It's also hard for Novo to ignore how Ozempic has in recent years become a household name and one frequently used in the media, by social media influencers and celebrities. Though often confused for Wegovy, the obesity brand of semaglutide, the name has become a cultural phenomenon.

This rebranding comes at a crucial time as competition intensifies in the oral GLP-1 space. Eli Lilly's oral GLP-1 drug Foundayo recently launched, and in its first week on the market, Lilly's Foundayo—starting from April 6—drew 1,390 prescriptions, according to IQVIA data. By comparison, the Wegovy pill garnered a little over 3,000 prescriptions during its launch week in January.

Expanding Access Through Multiple Channels

The launch strategy goes beyond traditional pharmacies. Semaglutide will be accessible in an oral version in numerous doses at more than 70,000 pharmacies. The company is also working with telehealth providers to expand access through digital channels, recognizing that many people prefer the convenience and privacy of online consultations for diabetes management.

Prescribing a medication with a guaranteed, transparent cash price allows the conversation to stay focused on clinical outcomes rather than insurance coverage. In 2026, the success of a drug will be defined not only by its efficacy, but by the transparency of its price tag.

What This Means for You

If you're currently taking injectable Ozempic or have been considering GLP-1 treatment but hesitated due to needles, this launch opens new possibilities. The Ozempic pill offers the same proven benefits for blood sugar control and cardiovascular risk reduction as the injection, but in a more convenient daily tablet format.

For those paying out of pocket, the $149 starting price represents a significant cost reduction compared to many injection options. Even if you have insurance, the simplified brand structure under Ozempic may make prior authorization discussions with your healthcare provider more straightforward. If you're looking for affordable options in your area, you can compare costs and explore whether local providers offer these new cash-pay pricing options.

To get started, consider consulting with providers who understand the full range of GLP-1 options, including both injectable semaglutide and these new oral formulations. Many GLP-1 clinics are already preparing to offer the new Ozempic pills alongside existing treatment options.